and is closely related to the onset of cervical cancer, and these pathologies are considered to be a public health global problem. 1 Approximately 80% of the sexually active population is infected with any subtype of HPV. 3 Most lesions regress without treatment within a period of up to 24 months as a result of the immune response, however, occasionally 10 to 30% of infections persist and may progress to high-grade lesions (CIN 2/3). 5 There are approximately 200 HPV genotypes and these may be related to low (CIN 1) or high grade (CIN 2/3). The main risk factor for the development of CIN is the persistence or relapse of high-risk HPV, especially subtypes 16 and 18 that are present in up to 75% of lesions. 6 These viruses express proteins that promote cell cycle alteration inducing genomic instability in normal cells, inhibiting apoptosis, favoring the formation of mitotic defects and aneuploidy. In addition, they inhibit tumor suppressor genes and modulate the immune system making the tumor cells low immunogenic, which results in immunological tolerance to the tumor and favors the HPV-mediated oncogenicity. 7, 8 When the virus is detected, the therapy of choice is the physical removal of the lesion, which is able to eliminate more than 80% of initial lesions. However, viral DNA often remains 9 and may lead to a recurrence of the lesion that may progress to cervical cancer 10 requiring more aggressive treatments, such as chemotherapy and radiotherapy, resulting in the death of 50% of patients. 11 On the other hand, treatments that stimulate the immune response have been shown to eliminate up to 90% of CIN 2 lesions upon 24 months. 13 Therefore, new therapeutic strategies that effectively and permanently eliminate the HPV virus are currently needed. 12 The production of therapeutic vaccines focuses on the effectiveness of specific immunological responses against antigens 14, 15 in order to eliminate the established pathology or prevent the patient from being reinfected, neutralizing subsequent infections by the same virus. Because of this characteristic, therapeutic vaccines differ significantly from the available prophylactic vaccines because these later are ineffective in treating established lesions and therefore have no therapeutic properties. 16 Moreover, because the risk population continues to be exposed to the virus without having an associated protective factor, therapeutic vaccines have low adherence rates and therefore the picture of HPV infections that can progress to aggressive pathologies remains unchanged. 17 Hence, based on the fact that HPV infections are frequent and associated with significant public health morbidity and mortality, it is necessary to develop effective and safe therapeutic vaccines against already established HPV-associated lesions. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) checklist as guidance, 18 we propose a systematic and reproducible strategy to query the literature about the safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus (HPV).
RESEARCH AIMS
The main objectives of this systematic review are: (1) To evaluate the efficacy of therapeutic vaccines in patients with high-grade cervical intraepithelial neoplasia, evaluated through histopathological regression of the lesion as well as regression of lesion size or other parameters that the authors considered relevant to assess this variable; (2) To assess the safety of therapeutic vaccines in patients with high-grade cervical intraepithelial neoplasia, reporting possible adverse effects to its administration; (3) To assess the immunogenicity of therapeutic vaccines in patients with high-grade cervical intraepithelial neoplasia by evaluating changes in the immunological profile of individuals who received the treatment compared to those who did not receive it.
METHODS AND ANALYSIS

Search Strategy
The search strategy will be carried out using resources that enhance methodological transparency and improve the reproducibility of the results and evidence synthesis. The search strategy will be elaborated and implemented prior to study selection, according to the PRISMA-P checklist as guidance. 18 In addition, using the PICOS acronym 19 Library Online) and Scopus. There will be no restriction regarding publication date. Language restrictions will be applied and only articles in English will be included. Additionally, secondary searches in other sources, such as, Google Scholar and registration sites of clinical trials (e.g. ClinicalTrials.gov) will be also carried out. Also, the reference section of the included studies will be hand searched for additional relevant studies. It is noteworthy that two researchers (CAG and LCLJ) will perform the search strategy independently. In addition, the bibliographic software EndNote (https://www.myendnoteweb.com/) will be used to store, organize, and manage all the references and ensure a systematic and comprehensive search.
Initially, the existence of controlled descriptors (such as MeSH terms, Emtree terms, and DeCS-Health Science Descriptors) and their synonyms (key words) was verified in each database. The search terms were combined using the Boolean operators "AND" and "OR". 20 Subsequently, the search strategy combining MeSH terms and free-text words that will be used in MEDLINE (via PubMed) and adjusted to the other electronic databases will be as follows in Table 1 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Study selection criteria
A summary of the population (P), interventions (I), comparators (C) and outcomes (O) considered, as well as studies designs (S) included according to PICOS acronym, is provided in Table 2 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Screening and data extraction
Initially the screening of studies will be based on the information contained in their titles and abstracts and will be conducted by two independent investigators (CAG and LCLJ).
When the reviewers disagree, the article will be reevaluated and, if the disagreement persisted, a third reviewer (GPS) will make a final decision. Full-paper screening will be conducted by the same independent investigators. Cohen's kappa will be used to measure inter-coder agreement in each screening phase.
Data will be extracted using previously proposed tools [21] [22] [23] , including four domains: i) identification of the study (article title; journal title; impact factor of the journal; authors; country of the study; language; publication year; host institution of the study [hospital;
university; research center; single institution; multicenter study]); ii) methodological characteristics (study design; study objective or research question or hypothesis; sample characteristics, e.g. sample size, age, race, baseline characteristics; groups and controls; recruitment methods and study completion rates; stated length of follow-up; validated measures; statistical analyses, adjustments; iii) main findings and implications for clinical practice; and iv) conclusions.
In the event that the information in any specific article is unclear or data are missing, the review author will contact the correspondent author of the study. For data extraction two independent Microsoft Excel spreadsheets will be elaborated by two reviewers (CAG and LCLJ) to summarize the data from the included studies. Then, the spreadsheets will be combined into one. Disagreements will be resolved by a third investigator (GPS). 
Quality assessment
Methodological quality of the RCTs will be assessed using the Jadad scale, 24 a widely used tool for classification of the quality of the evidence from RCTs. The Jadad scale scores range from 0 to 5, with studies scoring < 3 considered as low quality, and studies that score ≥ 3 classified as high quality. 24 The internal validity and risk of bias for RCTs will be assessed with the appraisal tool from the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0, 25 which assesses the following study-level aspects: (1) randomization sequence allocation; (2) allocation concealment; (3) blinding; (4) completeness of outcome data and (5) selective outcome reporting; and classifies studies into low, high or unclear risk of bias.
The same two independent reviewers (CAG and LCLJ) will assess the methodological quality of eligible trials as well as will score the selected studies. Disagreements will be resolved by a third reviewer (GPS). The risk of bias for each outcome across individual studies will be summarized as a narrative statement, and supported by a risk of bias table. A review-level narrative summary of the risk of bias will also be provided.
Descriptive analysis and meta-analysis
For studies with a high or unclear risk of bias, defined as high or nuclear risk in 50% or more of the quality assessment outcomes, a narrative description of the risk of bias will be provided. Risk of Bias assessments will be incorporated into synthesis by performing sensitivity analysis (i.e., limiting to studies at lowest risk of bias in a secondary analysis).
A narrative synthesis will be conducted for all the selected studies, including: i) characteristics related to the quality of the selected studies as number of drop-outs per followup, early withdrawal by benefit, intention-to-treat analysis, blindness scheme, allocation secrecy and randomization; ii) characteristics of the protocol used in studies such as type of intervention and control group, sample size, treatment time, dose and interval of the vaccine administration; iii) study population characteristics, such as, age, staging of disease, association of treatments or surgeries and other relevants information; iv) outcomes, for instance, the changes in immunological parameters, signs of local and systemic toxicity, histopathological regression of the lesion, regression of lesion size or reduction of viral load.
Furthermore, whenever possible, continuous and dichotomous outcomes will be pooled together for meta-analysis purposes. All effect sizes will be transformed into a common metric, in order to make them comparable across studies -the bias-corrected standardised difference in means (Hedges' g) -classified as positive when in favour of the intervention and negative when in favour of the control. Heterogeneity will be assessed using 
Patient and public involvement, ethics and dissemination
Patients were not directly involved in the design of this study. Because this is a protocol for a systematic review and no participant recruitment will take place, their involvement on the recruitment and dissemination of findings to participants was not applicable. Additionally, any amendments to this protocol will be documented with reference to saved searches and analysis methods, which will be recorded in bibliographic databases (Ovid), EndNote and Excel templates for data collection and synthesis.
The results of the review will be disseminated via peer-reviewed publication as well as in different media, e.g. conferences, congresses or symposia.
DISCUSSION
One of the strengths of the proposed study is to apply a reproducible and transparent procedure for systematic review of the literature. In this protocol, we clearly describe the types of studies, participants, interventions and outcomes that will be included, as well as the data sources, search strategy, data extraction methods (including quality assessment) and methods of combining data. 28 By publishing the research protocol, we reinforce the clarity of the strategy and minimize the risk of bias, namely selective outcome reporting. 25 Second, we will focus solely on the impact of the safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus (HPV). These results shall provide high-level information to inform, support and customize decisions from the oncology clinicians.
Potential limitations of this study include the heterogeneity of measures and outcomes evaluated and the potentially reduced number of studies in subgroup analyses, which may negatively influence the statistical power in data synthesis.
It is noteworthy that although prophylactic vaccines against HPV are safe and provide protective immunity against viruses that cause high-grade cancers 3, 29, 30 , the adherence to these vaccines is low, impairing an effective prevention against the development of this disease as well as cervical cancer. Low adherence to the vaccination also allows the spread of Sexually
Transmitted Diseases associated with this pathogen, constituting a serious global problem for public health. Once the disease is already in activity, prophylactic vaccines are no longer effective, and therefore effective and safe therapeutic vaccines that also activate a memory Reporting checklist for protocol of a systematic review.
Based on the PRISMA-P guidelines.
Instructions to authors
Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.
Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.
Upload your completed checklist as an extra file when you submit to a journal.
In your methods section, say that you used the PRISMA-P reporting guidelines, and cite them as:  The scarcity of of randomized controlled trials undertaken with therapeutic vaccines in the treatment of patients with CIN 2/3 associated with HPV, the publication bias and the methodological quality of the grey literature found may be the main limitations of the study. 4 and is closely related to the onset of cervical cancer, and these pathologies are considered to be a public health global problem. 1 Approximately 80% of the sexually active population is infected with any subtype of HPV. 3 Most lesions regress without treatment within a period of up to 24 months as a result of the immune response, however, occasionally 10 to 30% of infections persist and may progress to high-grade lesions (CIN 2/3). 5 There are approximately 200 HPV genotypes and these may be related to low (CIN 1) or high grade (CIN 2/3). The main risk factor for the development of CIN is the persistence or relapse of high-risk HPV, especially subtypes 16 and 18 that are present in up to 75% of lesions. 6 These viruses express proteins that promote cell cycle alteration inducing genomic instability in normal cells, inhibiting apoptosis, favoring the formation of mitotic defects and aneuploidy. In addition, they inhibit tumor suppressor genes and modulate the immune system making the tumor cells low immunogenic, which results in immunological tolerance to the tumor and favors the HPV-mediated oncogenicity. 7, 8 When the virus is detected, the therapy of choice is the physical removal of the lesion, which is able to eliminate more than 80% of initial lesions. However, viral DNA often remains 9 and may lead to a recurrence of the lesion that may progress to cervical cancer 10 requiring more aggressive treatments, such as chemotherapy and radiotherapy, resulting in the death of 50% of patients. 11 On the other hand, treatments that stimulate the immune response have been shown to eliminate up to 90% of CIN 2 lesions upon 24 months. 12 Therefore, new therapeutic strategies that effectively and permanently eliminate the HPV virus are currently needed. 12, 13 The production of therapeutic vaccines focuses on the effectiveness of specific immunological responses against antigens 14, 15 in order to eliminate the established pathology 16 Moreover, because the risk population continues to be exposed to the virus without having an associated protective factor, therapeutic vaccines have low adherence rates and therefore the picture of HPV infections that can progress to aggressive pathologies remains unchanged. 17 Hence, based on the fact that HPV infections are frequent and associated with significant public health morbidity and mortality, it is necessary to develop effective and safe therapeutic vaccines against already established HPV-associated lesions. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) checklist as guidance, 18 we propose a systematic and reproducible strategy to query the literature about the safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus (HPV).
RESEARCH AIMS
The main objectives of this systematic review are: 
METHODS AND ANALYSIS
Search Strategy
The search strategy will be carried out using resources that enhance methodological transparency and improve the reproducibility of the results and evidence synthesis. The search strategy will be elaborated and implemented prior to study selection, according to the PRISMA-P checklist as guidance. 18 In addition, using the PICOS acronym 19 we elaborated the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Library Online) and Scopus. There will be no restriction regarding publication date. Language restrictions will be applied and only articles in English will be included. Additionally, secondary searches in other sources, such as, Google Scholar and registration sites of clinical trials (e.g. ClinicalTrials.gov) will be also carried out. Also, the reference section of the included studies will be hand searched for additional relevant studies. It is noteworthy that two researchers (CAG and LCLJ) will perform the search strategy independently. In addition, the bibliographic software EndNote (https://www.myendnoteweb.com/) will be used to store, organize, and manage all the references and ensure a systematic and comprehensive search.
Initially, the existence of controlled descriptors (such as MeSH terms, Emtree terms, and DeCS-Health Science Descriptors) and their synonyms (key words) was verified in each database. The search terms were combined using the Boolean operators "AND" and "OR". 20 Subsequently, the search strategy combining MeSH terms and free-text words that will be used in MEDLINE (via PubMed) and adjusted to the other electronic databases will be as follows in Table 1 . 
Study selection criteria
A summary of the population (P), interventions (I), comparators (C) and outcomes (O) considered, as well as studies designs (S) included according to PICOS acronym, is provided in Table 2 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Patients with other immunosuppression associated conditions.
I -Intervention
Use of therapeutic vaccines for the treatment of high-grade cervical intraepithelial neoplasia (CIN 2 and 3) associated with HPV.
C -Comparison
Usual standard of care without receiving the therapeutic vaccine. O -Outcome
The safety, the efficacy and the immunogenicity of the therapeutic vaccines used in patients with highgrade cervical intraepithelial neoplasia (CIN 2 and 3) associated with HPV Studies that do not report safety, the efficacy for CIN 2 and 3 and the immunogenicity* of the therapeutic vaccines as primary outcome
S -Study design
Clinical trial
All the non-primary literature, such as reviews, dissertations, theses, editorials, protocol studies and clinical guidelines.
*Immunogenicity will be evaluated across the various studies in exploratory way in the blood and in the target tissue (including immune response to vaccine antigen assessment of HPV-specific CD8 and CD4 immune response; or also, via systemic induction of HPV E6-and E7-specific T-cell immune responses and changes of involved lesions and HPV infection status at the uterine cervix), among other parameters (e.g. generation of antibodies and release of cytokines).
Screening and data extraction
university; research center; single institution; multicenter study]; conflict of interest and study sponsorship); ii) methodological characteristics (study design; study objective or research question or hypothesis; sample characteristics, e.g. sample size, age, race, baseline characteristics; groups and controls; recruitment methods and study completion rates; stated length of follow-up; validated measures; statistical analyses, adjustments; iii) main findings and implications for clinical practice; and iv) conclusions.
Quality assessment
The internal validity and risk of bias for RCTs will be assessed with the appraisal tool from the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0, 24 which assesses the following study-level aspects: (1) randomization sequence allocation; (2) allocation concealment; (3) blinding; (4) completeness of outcome data and (5) selective outcome reporting; and classifies studies into low, high or unclear risk of bias. In addition, the quality evidence of the risk of bias in single studies, will be evaluated by the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) 25 .
Descriptive analysis and meta-analysis
A narrative synthesis will be conducted for all the selected studies, including: i) characteristics related to the quality of the selected studies as number of drop-outs per followup, early withdrawal by benefit, intention-to-treat analysis, blindness scheme, allocation secrecy and randomization; ii) characteristics of the protocol used in studies such as type of intervention and control group, sample size, treatment time, dose and interval of the vaccine administration; iii) study population characteristics, such as, age, staging of disease, association of treatments or surgeries and other relevant information; iv) outcomes, for instance, the changes in immunological parameters, signs of local and systemic toxicity, histopathological regression of the lesion, regression of lesion size or reduction of viral load.
Furthermore, whenever possible, continuous and dichotomous outcomes will be pooled together for meta-analysis purposes. All effect sizes will be transformed into a common metric, in order to make them comparable across studies -the bias-corrected standardised difference in means (Hedges' g) -classified as positive when in favour of the intervention and negative when in favour of the control. Heterogeneity will be assessed using 26 The presence of publication bias will be evaluated by using a funnel plot and the Duval and Tweedie's trim and fill method. 27 Therefore, we will assess the publication bias if enough studies per outcome are identified.
Patient and public involvement, ethics and dissemination
DISCUSSION
It is noteworthy that although prophylactic vaccines against HPV are safe and provide protective immunity against viruses that cause high-grade cancers 3, 29, 30 , the adherence to these vaccines is low, impairing an effective prevention against the development of this disease as well as cervical cancer. Low adherence to the vaccination also allows the spread of Sexually Transmitted Diseases associated with this pathogen, constituting a serious global problem for public health. Once the disease is already in activity, prophylactic vaccines are no longer Reporting checklist for protocol of a systematic review.
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